Inhibrx Biosciences, Inc. (INBX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$112.86-1.29%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — achieving revenue of at least $57 million in FY27: revenue 0.0 vs 57.0M.
Inhibrx is developing new biological therapies with potential future revenue. Analysts expect revenue of about $57 million in 2027. The company has stable management and no recent guidance cuts. If clinical trials succeed, earnings losses could narrow from -$9.26 to -$6.3 per share by next year.
Inhibrx has missed earnings estimates in the last three quarters and faces ongoing litigation. It remains unprofitable with negative free cash flow yield of -8%. Analysts expect EPS losses to deepen to -$9.26 this year. The recent 29% share price drop signals market doubts about recovery.
The market reflects elevated risk with a 29% drawdown and no clear consensus on revenue growth. Analysts expect continued losses through 2027. Our view differs by focusing on potential turnaround if clinical progress improves, but risks remain high.
Breaks if: EPS losses worsen or remain below -6.3 in FY27
Breaks if: new material litigation filed or existing litigation worsens
Breaks if: revenue fails to reach $57 million in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, as INBX is focused on advancing its clinical programs while facing significant cash burn. The current thesis state indicates a cautious approach, with recent performance showing signs of improvement but still under scrutiny.
The market appears to reflect a low fragility tier, suggesting that while the valuation is expensive, it does not fully account for the risks associated with the company's losses and operational challenges. Investors seem to expect continued progress in clinical development but remain wary of potential setbacks.
Fundamentals are likely to remain mixed in the near term, as management is focused on advancing clinical trials while managing cash burn. The company has reported consistent losses, and there is a notable risk of missing future performance expectations, which could impact sentiment.
The long-term thesis hinges on the outcomes of clinical trials and the ability to secure additional financing. Additionally, performance of sector bellwethers like VRTX, REGN, and ARGX will be critical, as their success or failure could influence the broader healthcare sector and INBX's trajectory.
Overall, INBX's path forward is uncertain, with both opportunities and risks ahead. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the thesis. Positive cancer drug trial results advance clinical development programs, further reinforcing the outlook.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.